Skip to main content
Erschienen in:

01.03.2025 | Editorial

Interdisziplinärer Diskurs zwischen der pädiatrischen und der internistischen Rheumatologie

Auf der Suche nach Antworten für gemeinsame Anliegen

verfasst von: Prim. Prof. Dr. Christian Huemer

Erschienen in: rheuma plus | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Auszug

Liebe Kolleginnen und Kollegen aus der Rheumatologie, …
Literatur
1.
Zurück zum Zitat Vermeer E, Hebing RCG, van de Meeberg MM et al (2023) Oral versus subcutaneous methotrexate in immune-mediates inflammatory disorders: an update of the current literature. Curr Rheumatol Rep 25(12):276–284CrossRefPubMedPubMedCentral Vermeer E, Hebing RCG, van de Meeberg MM et al (2023) Oral versus subcutaneous methotrexate in immune-mediates inflammatory disorders: an update of the current literature. Curr Rheumatol Rep 25(12):276–284CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bakry R, Klein MA, Horneff G (2022) Oral or parenteral methotrexate for the treatment of polyarticular juvenile idiopathic arthritis. Eur J Rheumatol 9(4):197–205CrossRefPubMedPubMedCentral Bakry R, Klein MA, Horneff G (2022) Oral or parenteral methotrexate for the treatment of polyarticular juvenile idiopathic arthritis. Eur J Rheumatol 9(4):197–205CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Pradeu T, Jaeger S, Vivier E (2013) The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol 13(10):764–769CrossRefPubMed Pradeu T, Jaeger S, Vivier E (2013) The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol 13(10):764–769CrossRefPubMed
4.
Zurück zum Zitat Thomas SS, Borazan N, Barroso N et al (2015) Comparative Immunogenicity of TNF-inhibitors:impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 29(4):241–258CrossRefPubMed Thomas SS, Borazan N, Barroso N et al (2015) Comparative Immunogenicity of TNF-inhibitors:impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 29(4):241–258CrossRefPubMed
5.
Zurück zum Zitat Rutgeerts P, Freagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of Infliximab in Crohns’s disease. Gastroenterology 126(2):402–413CrossRefPubMed Rutgeerts P, Freagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of Infliximab in Crohns’s disease. Gastroenterology 126(2):402–413CrossRefPubMed
6.
Zurück zum Zitat Klotsche J, Minden K, Niewerth M et al (2018) Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Ann Rheum Dis 77:996–1002CrossRefPubMed Klotsche J, Minden K, Niewerth M et al (2018) Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Ann Rheum Dis 77:996–1002CrossRefPubMed
7.
Zurück zum Zitat Klotsche J, Klein A, Niewerth M et al (2021) Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis. Arthritis Res Ther 23:118CrossRefPubMedPubMedCentral Klotsche J, Klein A, Niewerth M et al (2021) Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis. Arthritis Res Ther 23:118CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Lovell DJ, Johnson AL, Huang B et al (2018) Risk, timing, and predictors of disease flare after discontinuation of anti tumor necrosis factor therapy in children with polyarticular forms of juvenile Idopathic arthritis with clinically inactive disease. Arthritis Rheumatol 70:1508–1518CrossRefPubMedPubMedCentral Lovell DJ, Johnson AL, Huang B et al (2018) Risk, timing, and predictors of disease flare after discontinuation of anti tumor necrosis factor therapy in children with polyarticular forms of juvenile Idopathic arthritis with clinically inactive disease. Arthritis Rheumatol 70:1508–1518CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Halyabar O, Mehta J, Ringold S et al (2019) Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Paediatr Drugs 21:469–492CrossRefPubMedPubMedCentral Halyabar O, Mehta J, Ringold S et al (2019) Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Paediatr Drugs 21:469–492CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Foell D, Wulffraat N, Wedderburn LR et al (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303:1266–1273CrossRefPubMed Foell D, Wulffraat N, Wedderburn LR et al (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303:1266–1273CrossRefPubMed
11.
Zurück zum Zitat Gerss J, Tedy M, Klein A et al (2022) Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile Idopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis 81:990–997CrossRefPubMed Gerss J, Tedy M, Klein A et al (2022) Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile Idopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis 81:990–997CrossRefPubMed
12.
13.
Metadaten
Titel
Interdisziplinärer Diskurs zwischen der pädiatrischen und der internistischen Rheumatologie
Auf der Suche nach Antworten für gemeinsame Anliegen
verfasst von
Prim. Prof. Dr. Christian Huemer
Publikationsdatum
01.03.2025
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 1/2025
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-025-00829-0